CNOOC Limited Brings On-stream Xijiang Oilfields 24 Block Development Project
HONG KONG, Dec. 22, 2025 /PRNewswire/ -- CNOOC Limited (the "Company", SEHK: 00883 (HKD Counter) and 80883 (RMB Counter), SSE: 600938) today announces that Xijiang Oilfields 24 Block Development Project has commenced production. The project is...
Samsung to Host Series of Tech Forums at CES 2026
F orum discussions will feature a moderated panel of experts from across the technology industry to explore the latest trends in AI, Home Appliances, Services and Design SEOUL, South Korea, Dec. 22, 2025 /PRNewswire/ -- Samsung Electronics Co., Ltd....
LG Innotek Launches World's First 'Next-Generation Smart IC Substrate'
Cuts carbon dioxide emissions from its production by 50%—equivalent to planting 1.3 million trees annually. Boosts durability by up to three times for secure information recognition even with long-term use. Mass production tailored to global...
Samsung To Unveil AI Vision Built With Google Gemini at CES 2026
With the upgraded AI Vision, Samsung becomes more fluent in food recognition and expands the reach of kitchen experiences Company will also showcase a new Bespoke AI Wine Cellar and newly designed cooking appliances SEOUL, South Korea, Dec. 22, 2025...
Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions
MELBOURNE, Australia and INDIANAPOLIS, Dec. 22, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today provides a precision medicine portfolio update in relation to: TLX591-CDx (Illuccix® in approved jurisdictions,...
T-MAXIMUM Pharmaceutical's Allogeneic CAR-T Therapy MT027 Receives FDA IND Clearance to Proceed to Phase II clinical Trial for Recurrent Glioblastoma
BEIJING, Dec. 21, 2025 /PRNewswire/ -- T-MAXIMUM Pharmaceutical announced that its proprietary allogeneic, B7-H3-targeted CAR-T therapy, MT027, has received IND Clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase II...
Jacobio Pharma Enters Global Exclusive License Agreement with AstraZeneca for Pan-KRAS Inhibitor JAB-23E73
BEIJING, SHANGHAI and BOSTON, Dec. 21, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK,) today announced that it has entered an agreement with AstraZeneca for its proprietary Pan-KRAS inhibitor JAB-23E73. AstraZeneca will receive exclusive development...
Vantage Markets recognised for real-time threat intelligence collaboration with Trend Micro
Innovation Partnership Award highlights deep collaboration, real-time intelligence sharing, and advanced security deployment across one of Australia's leading financial trading platforms SYDNEY, Dec. 21, 2025 /PRNewswire/ -- Trend Micro Incorporated...